{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:47:53Z","timestamp":1790401673817,"version":"4.1.0"},"reference-count":43,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:italic>Plasmodium falciparum<\/jats:italic> sporozoite (PfSPZ) Vaccine (radiation-attenuated, aseptic, purified, cryopreserved PfSPZ) and PfSPZ-CVac (infectious, aseptic, purified, cryopreserved PfSPZ administered to subjects taking weekly chloroquine chemoprophylaxis) have shown vaccine efficacies (VEs) of 100% against homologous controlled human malaria infection (CHMI) in nonimmune adults. <jats:italic>Plasmodium falciparum<\/jats:italic> sporozoite-CVac has never been assessed against CHMI in African vaccinees. We assessed the safety, immunogenicity, and VE against homologous CHMI of three doses of 2.7 \u00d7 10<jats:sup>6<\/jats:sup> PfSPZ of PfSPZ Vaccine at 8-week intervals and three doses of 1.0 \u00d7 10<jats:sup>5<\/jats:sup> PfSPZ of PfSPZ-CVac at 4-week intervals with each arm randomized, double-blind, placebo-controlled, and conducted in parallel. There were no differences in solicited adverse events between vaccinees and normal saline controls, or between PfSPZ Vaccine and PfSPZ-CVac recipients during the 6 days after administration of investigational product. However, from days 7\u201313, PfSPZ-CVac recipients had significantly more AEs, probably because of Pf parasitemia. Antibody responses were 2.9 times higher in PfSPZ Vaccine recipients than PfSPZ-CVac recipients at time of CHMI. Vaccine efficacy at a median of 14 weeks after last PfSPZ-CVac dose was 55% (8 of 13, <jats:italic>P<\/jats:italic> = 0.051) and at a median of 15 weeks after last PfSPZ Vaccine dose was 27% (5 of 15, <jats:italic>P<\/jats:italic> = 0.32). The higher VE in PfSPZ-CVac recipients of 55% with a 27-fold lower dose was likely a result of later stage parasite maturation in the liver, leading to induction of cellular immunity against a greater quantity and broader array of antigens.<\/jats:p>","DOI":"10.4269\/ajtmh.20-0435","type":"journal-article","created":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T07:01:06Z","timestamp":1605596466000},"page":"283-293","source":"Crossref","is-referenced-by-count":59,"title":["Immunogenicity and Protective Efficacy of Radiation-Attenuated and Chemo-Attenuated PfSPZ Vaccines in Equatoguinean Adults"],"prefix":"10.4269","volume":"104","author":[{"given":"Said A.","family":"Jongo","sequence":"first","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Urbano","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. W. Preston","family":"Church","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ally","family":"Olotu","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Manock","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Schindler","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mtoro","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"},{"name":"5Protein Potential LLC, Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Hamad","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Nyakarungu","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximillian","family":"Mpina","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Deal","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Raso","family":"Bijeri","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Eka","family":"Ondo Mangue","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beltr\u00e1n Ekua","family":"Ntutumu Pasialo","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genaro Nsue","family":"Nguema","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon Nguema","family":"Owono","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde Riloha","family":"Rivas","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mwajuma","family":"Chemba","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaka R.","family":"Kassim","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"James","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Stabler","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonas","family":"Abebe","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Saverino","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Sax","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Hosch","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneth-Mwasi","family":"Tumbo","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gondwe","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Luis","family":"Segura","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Cortes","family":"Falla","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonder Philip","family":"Phiri","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna E. B.","family":"Hergott","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo A.","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schwabe","sequence":"additional","affiliation":[{"name":"6Medical Care Development International, Silver Spring, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Maas","sequence":"additional","affiliation":[{"name":"7Marathon EG Production, Ltd., Bioko Norte, Equatorial Guinea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Tanner","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitoha Ondo\u2019o","family":"Ayekaba","sequence":"additional","affiliation":[{"name":"2Ministry of Health and Social Welfare, Government of Equatorial Guinea, Bioko Norte, Equatorial Guinea;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"},{"name":"5Protein Potential LLC, Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Daubenberger","sequence":"additional","affiliation":[{"name":"4Swiss Tropical and Public Health Institute, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Abdulla","sequence":"additional","affiliation":[{"name":"1Ifakara Health Institute, Bagamoyo Research and Training Centre, Bagamoyo, Tanzania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"3Sanaria Inc., Rockville, Maryland;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"b1","volume-title":"World Malaria Report 2018","year":"2018"},{"key":"b2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(19)31139-0","article-title":"Malaria eradication within a generation: ambitious, achievable, and necessary","volume":"394","author":"Feachem","year":"2019","journal-title":"Lancet"},{"key":"b3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"b4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12936-018-2213-9","article-title":"Trends in parasite prevalence following 13 years of malaria interventions on Bioko island, Equatorial Guinea: 2004\u20132016","volume":"17","author":"Cook","year":"2018","journal-title":"Malar J"},{"key":"b5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0140-6736(19)31951-8","article-title":"The malaria eradication challenge","volume":"394","author":"Ghebreyesus","year":"2019","journal-title":"Lancet"},{"key":"b6","doi-asserted-by":"crossref","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","article-title":"Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines","volume":"33","author":"Richie","year":"2015","journal-title":"Vaccine"},{"key":"b7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.1211548","article-title":"Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity","volume":"334","author":"Epstein","year":"2011","journal-title":"Science"},{"key":"b8","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder","year":"2013","journal-title":"Science"},{"key":"b9","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4269\/ajtmh.15-0621","article-title":"Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial","volume":"94","author":"Bastiaens","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"b10","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka","year":"2016","journal-title":"Nat Med"},{"key":"b11","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ vaccine","volume":"2","author":"Epstein","year":"2017","journal-title":"JCI Insight"},{"key":"b12","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1073\/pnas.1615324114","article-title":"Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection","volume":"114","author":"Lyke","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"b13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordmuller","year":"2017","journal-title":"Nature"},{"key":"b14","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"b15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults","volume":"99","author":"Jongo","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"b16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","article-title":"Advancing global Health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy Equatoguinean men","volume":"98","author":"Olotu","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"b17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","article-title":"Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants","volume":"100","author":"Jongo","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"b18","first-page":"ciz1152","article-title":"Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian adults","author":"Jongo","year":"2019","journal-title":"Clin Infect Dis"},{"key":"b19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/cid\/ciz925","article-title":"Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya","volume":"71","author":"Steinhardt","year":"2019","journal-title":"Clin Infect Dis"},{"key":"b20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.4161\/hv.6.1.10396","article-title":"Development of a metabolically active,non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria","volume":"6","author":"Hoffman","year":"2010","journal-title":"Hum Vaccin"},{"key":"b21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4269\/ajtmh.2012.12-0613","article-title":"Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites","volume":"88","author":"Roestenberg","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"b22","doi-asserted-by":"crossref","first-page":"e65960","DOI":"10.1371\/journal.pone.0065960","article-title":"Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe","volume":"8","author":"Sheehy","year":"2013","journal-title":"PLoS One"},{"key":"b23","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3389\/fmicb.2014.00686","article-title":"Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection","volume":"5","author":"Hodgson","year":"2014","journal-title":"Front Microbiol"},{"key":"b24","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","article-title":"Controlled human malaria infection of Tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites","volume":"91","author":"Shekalaghe","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"b25","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","article-title":"Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates","volume":"14","author":"Gomez-Perez","year":"2015","journal-title":"Malar J"},{"key":"b26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","article-title":"Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres","volume":"14","author":"Mordm\u00fcller","year":"2015","journal-title":"Malar J"},{"key":"b27","doi-asserted-by":"crossref","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","article-title":"Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon","volume":"98","author":"Lell","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"b28","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1093\/cid\/ciz740","article-title":"Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a Plasmodium falciparum controlled human infection","volume":"70","author":"Achan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"b29","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","article-title":"Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults","volume":"220","author":"Laurens","year":"2019","journal-title":"J Infect Dis"},{"key":"b30","doi-asserted-by":"crossref","first-page":"ciaa1294","DOI":"10.1093\/cid\/ciaa1294","article-title":"Multidose priming and delayed boosting improve PfSPZ vaccine efficacy against heterologous P. falciparum CHMI","author":"Lyke","year":"2020","journal-title":"Clin Infect Dis"},{"key":"b31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12936-019-2639-8","article-title":"Molecular monitoring of the diversity of human pathogenic malaria species in blood donations on Bioko Island, Equatorial Guinea","volume":"18","author":"Schindler","year":"2019","journal-title":"Malar J"},{"key":"b32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0035-9203(99)90120-7","article-title":"Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand","volume":"93","author":"Snounou","year":"1999","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"b33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1017\/S0031182099004552","article-title":"Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples","volume":"119","author":"Anderson","year":"1999","journal-title":"Parasitology"},{"key":"b34","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1128\/AAC.47.4.1347-1354.2003","article-title":"Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania","volume":"47","author":"Pearce","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"b35","doi-asserted-by":"crossref","first-page":"e011088","DOI":"10.1136\/bmjopen-2016-011088","article-title":"Weekly miscarriage rates in a community-based prospective cohort study in rural western Kenya","volume":"6","author":"Dellicour","year":"2016","journal-title":"BMJ Open"},{"key":"b36","volume-title":"Report on In Vitro Antimalarial Drug Sensitivities for Seven Lines of Plasmodium falciparum","author":"Barnwell","year":"2013"},{"key":"b37","doi-asserted-by":"crossref","first-page":"e31247","DOI":"10.1371\/journal.pone.0031247","article-title":"Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites","volume":"7","author":"Weiss","year":"2012","journal-title":"PLoS One"},{"key":"b38","doi-asserted-by":"crossref","first-page":"e88117","DOI":"10.1371\/journal.pone.0088117","article-title":"CD8(+) T cells mediate robust stage-specific immunity to P. berghei under chemoprophylaxis and this protective environment is not downregulated by the presence of blood-stage infection","volume":"9","author":"Lewis","year":"2014","journal-title":"PLoS One"},{"key":"b39","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/1475-2875-13-92","article-title":"Phenotypic characterization of Plasmodium berghei responsive CD8+ T cells after immunization with live sporozoites under chloroquine cover","volume":"13","author":"Brando","year":"2014","journal-title":"Malar J"},{"key":"b40","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","article-title":"DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection","volume":"17","author":"Sulyok","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"b41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/tmi.13357","article-title":"Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial","volume":"25","author":"Metzger","year":"2020","journal-title":"Trop Med Int Health"},{"key":"b42","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2","volume":"69","author":"Dejon-Agobe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"b43","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa0805832","article-title":"Protection against a malaria challenge by sporozoite inoculation","volume":"361","author":"Roestenberg","year":"2009","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/104\/1\/article-p283.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/104\/1\/article-p283.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T17:43:33Z","timestamp":1611769413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/104\/1\/article-p283.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":43,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.20-0435","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]}}}